NEW YORK (GenomeWeb) – Researchers from the CORRECT trial have provided additional evidence that genomic analysis of liquid biopsies could be a viable approach for keeping tabs on tumor genotype evolution and matching clinically relevant mutations to therapeutics.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.